1 min read
Add as a preferred source on Google

Integrated BioPharma Posts $0.02 Q3 GAAP Loss Per Share

Revenue came to $9.91 million, down 21.9% year over year. The company swung to a $110,000 gross loss from $1.02 million in gross profit a year earlier.

Amber capsules sit in a sparse, unmarked blister tray / TokenPost.ai
Amber capsules sit in a sparse, unmarked blister tray / TokenPost.ai

Integrated BioPharma, Inc. (INBP) recorded a $0.02 GAAP loss per share for the third quarter as revenue fell 21.9% year over year to $9.91 million, alongside weaker gross and operating results.

Gross results moved to a loss of $110,000 from $1.02 million in gross profit in Q3 2025. Cost of sales in the latest quarter totaled $10.03 million.

The company recorded an operating loss of $960,000, compared with operating income of $160,000 in Q3 2025.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…